Matthew Preszler
Toledo, OHNPI 1902545528
Payments from drug & device makers
Across 75 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$197
- Teva Pharmaceuticals USA, Inc.$181
- AbbVie$145
- SK Life Science, Inc.$126
- CSL Behring$116
- E.r. Squibb & Sons, L.L.C.$105
- plus $673 from 16 others
What the payments were for
- Food & beverage$1,48896%
- Education$554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 12 | $197 |
| Teva Pharmaceuticals USA, Inc. | 7 | $181 |
| AbbVie | 6 | $145 |
| SK Life Science, Inc. | 7 | $126 |
| CSL Behring | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $105 |
| Merz Pharmaceuticals, LLC | 5 | $89 |
| Neurelis, Inc. | 4 | $85 |
| AstraZeneca(2 entities) | 4 | $63 |
| Pyros Pharmaceuticals, Inc. | 2 | $62 |
| EMD Serono, Inc. | 4 | $62 |
| Biogen | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Eisai Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Averitas Pharma Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$105
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 11 | $1,498 |
| Levetiracetam | 27 | $594 |
| Donepezil Hcl | 18 | $250 |
| ClopidogrelClopidogrel Bisulfate | 39 | $186 |
| Gabapentin | 17 | $149 |
| Lamotrigine | 13 | $126 |
| Atorvastatin Calcium | 32 | $121 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.